Patent details
LUC00280
Product Name:
Padcev - enfortumab vedotin
Basic Information
- Publication number:
- LUC00280
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
-
EP118313451
- Legal Status:
- Inactive
- Application number:
- LUC00280
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/21/1615
- Marketing Authorization Type:
-
- Marketing Authorization Date:
- 19/04/2022
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 06/10/2022
- First Marketing Authorization date:
- 19/04/2022
- Grant date:
- 12/05/2025
- Activation date:
- Publication date:
- 06/10/2022
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 29/09/2036
- SPC Extension Expiration:
- 29/09/2036
- Rejection date:
- Withdrawal date:
Owner
- From:
- 06/10/2022
-
-
- Name:
- AGENSYS, INC.
- Address:
- 1 Astellas Way,, 60062, Northbrook, IL, United States (US)
- Name:
- SEAGEN INC.
- Address:
- 21823 30th Drive, S.E., 98021, Bothell, WA , United States (US)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 06/10/2022
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Publication
Bulletin
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2022/12
- Publication date:
- 08/11/2022
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
Annual Fees
- Annual Fee Due Date:
- 30/09/2031
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
-
- Last Annual Fee Payment Date:
-
- Last Annual Fee Paid Number:
-
- Payer:
-